Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of COVID-19 Vaccine in Patients After Allogeneic Hamatopoietic Cell Transplantation, CAR-T Therapy and With Primary Immune Deficiency - a Post Marketing Prospective Cohort Study
Conditions
Locations
1
Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Start Date
December 28, 2020
Primary Completion Date
May 28, 2021
Completion Date
December 28, 2021
Last Updated
January 28, 2021
NCT03394053
NCT07140770
NCT04902807
NCT05755035
NCT03330795
NCT06955793
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions